Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
65 /100
COMPONENT-LIMITED
Score updated Aug 28, 2026

DMAA — Drugs Made In America Acquisition Corp. Dilution Risk Tracker

Track DMAA dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track DMAA — Get alerts when the score changes →

As of August 28, 2026, Drugs Made In America Acquisition Corp. (DMAA) has a DilutionWatch DilutionScore of 65/100, rated HIGH dilution risk. This is a component-limited score because one or more material inputs are unavailable or not applicable. Drugs Made In America Acquisition Corp. has a market capitalization of $257.58M, 24.28M shares outstanding, 39 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
36
💰 Cash Runway
95
📊Float Risk
⚠️ Warrant Exposure
40
🔄 Convertible Debt
40

Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
model est. 30%
💰 Capital Raise model 55%
• Critical: only 0.5 months cash remaining
📉 Score Deterioration model 10%
• Score in HIGH risk zone (65/100)
🔔 Track DMAA — Get forecast alerts →

Market Data

Market Cap$257.58M
Shares Outstanding24.28M
FloatN/A
Cash$20.3K
DebtN/A
Short InterestN/A

Institutional Holdings

QoQ: ↓ 9.5% shares (2026Q1 vs prior)
39 institutional holders · 24.31M shares
#1 Karpus Management, Inc. 2.53M shares
#2 First Trust Capital Management L.P. 2.24M shares
#3 MIZUHO SECURITIES USA LLC 2.00M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest88.7K
Days to Cover5.1
% of FloatN/A
FINRA data as of Jul 31, 2026

Recent SEC Activity

8-K 8K EVENT 2026-05-01
8-K 8K EVENT 2026-04-28
8-K 8K EVENT 2026-03-27
Full SEC filing analysis available with free account

Recent News

No recent news

Factual DMAA Dilution Snapshot

Drugs Made In America Acquisition Corp. (DMAA) has a DilutionScore of 65/100, rated High dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track DMAA Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking DMAA — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

→ SPAC / Warrants sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations

Score Coverage Note

More Research for DMAA
DMAA FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.